Catalyst

Slingshot members are tracking this event:

Having used Halozyme Therapuetics' ENHANZE technology ,Roche’s is awaiting June FDA action date on rituximab in chronic lymphocytic leukemia and non-Hodgkin's lymphoma

Source Link:
https://seekingalpha.com/article/4050797-halozyme-therapeutics-halo-ceo-helen-torley-q4-2016-results-earnings-call-transcript?page=4

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
HALO Community voting in process
RHHBY Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Jun 23, 2017
Occurred Source:
http://www.roche.com/investors/updates/inv-update-2017-06-23d.htm
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Rituximab, Chronic Lymphocytic Leukemia, Non-hodgkin's Lymphoma, Fda Review, Enhanze
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.